[Clinical testing of bronchospasmolytics in combined alternating test schedules].
NAB 365, a new beta2-adrenergic bronchodilator was tested in oral doses of 0.01, 0.02, 0.03 and 0.04 mg. An acute trial was carried out in outpatients suffering from chronic obstructive airways disease. Airway resistance was measured by bodyplethysmography. For doses from 0.02 to 0.04 mg NAB 365 a quick, dose related and statistically significant bronchodliation without remarkable side effects could be found. The application of Fenoterol and Sch 1000 (ipratropiumbromide) by a metered dose inhaler was followed by a further and finally equal bronchodilation. To avoid adrenergic side effects the combination of NAB 365 with Sch 1000 should be preferred to the combination of NAB 365 with Fenoterol.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000402:Airway Obstruction / Q000188:drug therapy*; D000403:Airway Resistance / Q000187:drug effects; D000814:Aniline Compounds / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005280:Fenoterol / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use; D008176:Lung Volume Measurements; D008297:Male; D008875:Middle Aged
D000318:Adrenergic beta-Agonists; D000814:Aniline Compounds; D001993:Bronchodilator Agents; D004983:Ethanolamines; D005280:Fenoterol; D009241:Ipratropium
Klinische Prüfung von Bronchospasmolytika in kombinierter alternierender Versuchsanordnung